Abstract:

Hyperphosphatemia is an independent risk factor for mortality in patients with chronic kidney disease (CKD). The prognosis of patients with CKD can be improved by effectively controlling the hyperphosphatemia. At present， the main measure of controlling the level of phosphorus includes limitting  dietary phosphorus intake， oral administration of phosphorus and dialysis. Among them， oral intestinal phosphate binding agent is the most convenient and effective method to reduce phosphorus in CKD patients.

Key words: kidney diseases, hyperphosphatemia, dialysis, phosphate binder, treatment